Genocea Biosciences (NASDAQ:GNCAQ – Get Free Report) and Exelixis (NASDAQ:EXEL – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Valuation & Earnings This table compares Genocea Biosciences and […]
WINTON GROUP Ltd reduced its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 88.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,732 shares of the biotechnology company’s stock after selling 192,453 shares during the quarter. WINTON GROUP Ltd’s holdings in […]
07.12.2023 - Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the .
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $22.01, for a total transaction of $550,250.00. Following the sale, the executive vice president now directly owns 583,345 shares in […]